# Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

> **NCT01014091** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK pandemic vaccine GSK2340272A

## Key facts

- **NCT ID:** NCT01014091
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12-01
- **Primary completion:** 2011-01-14
- **Final completion:** 2011-01-14
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01014091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01014091, "Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01014091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*